Novartis

Novartis, a global healthcare company, was established on December 20, 1996, through the merger of Ciba-Geigy and Sandoz. With its headquarters situated in Basel, Switzerland, the company focuses on several key business segments. The Innovative Medicines division is responsible for the development and distribution of patented prescription drugs that address serious health issues including oncology, cardiology, immunology, and neurology. Among the most influential brands under this division are Cosentyx, which is utilized in the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis; Entresto, for heart failure; Gilenya, for multiple sclerosis; and Lucentis, targeting various eye diseases. Additionally, Tasigna and Gleevec are notable contributions to the treatment of chronic myeloid leukemia. Another central segment is Sandoz, the generics and biosimilars arm of Novartis, which provides a broad array of generic options, such as those for dermatology, respiratory conditions, ophthalmology, and oncology. The company's global reach is extensive, with a presence in over 155 countries. Novartis has a significant market in the United States and holds a robust position in Europe. It is also expanding in emerging markets across Asia and Latin America, where its products and services cater to diverse healthcare needs. (Powered by AI)